15-hydroxyeicosatetraenoic acid (15-HETE) specifically inhibits the LTB4-induced skin response. 1989

T Ternowitz, and P H Andersen, and P Bjerring, and K Fogh, and J M Schröder, and K Kragballe
Department of Dermatology, Marselisborg Hospital, University, Aarhus C, Denmark.

15-Hydroxyeicosatetraenoic acid (15-HETE), a 15-lipoxygenase product of arachidonic acid, inhibits leukotriene B4 (LTB4)-induced chemotaxis of polymorphonuclear leukocytes (PMNs) in vitro. In this study the effects of intradermal injections of LTB4 were determined in the absence or presence of 15-HETE. For comparison intradermal injections of purified human complement split product C5a were performed in the absence or presence of 15-HETE. The skin response was evaluated by measuring the diameter of the wheal, the area of the flare and by intensity of the erythema (erythema index). LTB4 and C5a were injected at the concentration of 200 ng/ml. At this concentration the maximal skin response of LTB4 and C5a were equivalent. In contrast to C5a reaction, which resolved within 1 h, LTB4-induced skin response lasted up to 18 h. In all subjects the skin response was significantly decreased when LTB4 was injected together with 300 ng of 15-HETE. The decrease of wheal, flare, and erythema index averaged 81.9%, 56.6%, 53.6%, respectively, when all parameters were obtained at the maximal skin response. In contrast, the C5a-induced skin response was not affected by addition of 15-HETE, even when the final dose of 15-HETE was increased 10 times to 3 micrograms. The LTB4-induced reaction could last up to 18 h after injection. After the addition of 300 ng of 15-HETE the skin response resolved after 1 h. The present results demonstrate that 15-HETE is a specific inhibitor of the LTB4-induced skin response and brings additional evidence in support of the ability of 15-HETE to regulate the proinflammatory effects of LTB4 in vivo.

UI MeSH Term Description Entries
D007428 Intradermal Tests Skin tests in which the sensitizer is injected. Passive Transfer Test,Prausnitz-Kustner Test,Intradermal Test,Passive Transfer Tests,Prausnitz Kustner Test,Test, Intradermal,Test, Passive Transfer,Test, Prausnitz-Kustner,Tests, Intradermal,Tests, Passive Transfer
D007975 Leukotriene B4 The major metabolite in neutrophil polymorphonuclear leukocytes. It stimulates polymorphonuclear cell function (degranulation, formation of oxygen-centered free radicals, arachidonic acid release, and metabolism). (From Dictionary of Prostaglandins and Related Compounds, 1990) 5,12-HETE,5,12-diHETE,LTB4,Leukotriene B,Leukotriene B-4,Leukotrienes B,5,12 HETE,5,12 diHETE,B-4, Leukotriene,Leukotriene B 4
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004890 Erythema Redness of the skin produced by congestion of the capillaries. This condition may result from a variety of disease processes. Erythemas
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006893 Hydroxyeicosatetraenoic Acids Eicosatetraenoic acids substituted in any position by one or more hydroxy groups. They are important intermediates in a series of biosynthetic processes leading from arachidonic acid to a number of biologically active compounds such as prostaglandins, thromboxanes, and leukotrienes. HETE,Acids, Hydroxyeicosatetraenoic
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012867 Skin The outer covering of the body that protects it from the environment. It is composed of the DERMIS and the EPIDERMIS.

Related Publications

T Ternowitz, and P H Andersen, and P Bjerring, and K Fogh, and J M Schröder, and K Kragballe
January 1988, Skin pharmacology : the official journal of the Skin Pharmacology Society,
T Ternowitz, and P H Andersen, and P Bjerring, and K Fogh, and J M Schröder, and K Kragballe
January 1984, Prostaglandins, leukotrienes, and medicine,
T Ternowitz, and P H Andersen, and P Bjerring, and K Fogh, and J M Schröder, and K Kragballe
February 1989, Prostaglandins,
T Ternowitz, and P H Andersen, and P Bjerring, and K Fogh, and J M Schröder, and K Kragballe
January 1987, Advances in prostaglandin, thromboxane, and leukotriene research,
T Ternowitz, and P H Andersen, and P Bjerring, and K Fogh, and J M Schröder, and K Kragballe
November 1992, The Journal of biological chemistry,
T Ternowitz, and P H Andersen, and P Bjerring, and K Fogh, and J M Schröder, and K Kragballe
January 1991, Advances in prostaglandin, thromboxane, and leukotriene research,
T Ternowitz, and P H Andersen, and P Bjerring, and K Fogh, and J M Schröder, and K Kragballe
February 1988, Journal of the American Academy of Dermatology,
T Ternowitz, and P H Andersen, and P Bjerring, and K Fogh, and J M Schröder, and K Kragballe
August 1986, Archives of dermatology,
T Ternowitz, and P H Andersen, and P Bjerring, and K Fogh, and J M Schröder, and K Kragballe
May 1992, Kidney international,
T Ternowitz, and P H Andersen, and P Bjerring, and K Fogh, and J M Schröder, and K Kragballe
July 1990, Prostaglandins, leukotrienes, and essential fatty acids,
Copied contents to your clipboard!